Opposing Role of Mitogen-activated Protein Kinase Subtypes, Erk-1/2 and p38, in the Regulation of Chondrogenesis of Mesenchymes*

Abstract

The present studies were performed to determine subtype-specific roles of mitogen-activated protein kinase in chondrogenesis. Erk-1/2 activities, downstream of protein kinase C, decreased as chondrogenesis proceeded, whereas p38 activities, independent of protein kinase C, continuously increased during chondrogenesis. Inhibition of Erk-1/2 with PD98059 enhanced chondrogenesis up to 1.7-fold, whereas inhibition of p38 with SB203580 reduced it to about 30% of the control level. Inhibition of Erk-1/2 or p38 did not affect precartilage condensation. However, cartilage nodule formation was significantly blocked by the inhibition of p38, whereas Erk-1/2 inhibition did not affect it. Modulation of chondrogenesis by the inhibition of Erk-1/2 and p38 was accompanied by altered expression of adhesion molecules in an opposite way. Expression ofN-cadherin was reduced as chondrogenesis proceeded. Inhibition of p38 caused sustained expression ofN-cadherin, whereas Erk-1/2 inhibition accelerated the reduction of N-cadherin expression. Expression of integrin α5β1 and fibronectin were found to transiently increase during chondrogenesis. Inhibition of p38 caused continuous increase of expression of these molecules, whereas Erk-1/2 inhibition accelerated the decrease of expression of these molecules at a later period of chondrogenesis. Because temporal expression of these adhesion molecules regulates chondrogenesis, the above results indicate that Erk-1/2 and p38 conversely regulate chondrogenesis at post-precartilage condensation stages by modulating expression of adhesion molecules.

  • Abbreviations:
    ECM
    extracellular matrix
    PKC
    protein kinase C
    MAP kinase
    mitogen-activated protein kinase
    PNA
    peanut agglutinin
    Erk
    extracellular signal-regulated kinase
    • Received August 25, 1999.
    • Revision received December 3, 1999.
    Table of Contents

    Submit your work to JBC.

    You'll be in good company.